FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to the field of biochemistry and biotechnology. Claimed hyaluronodase from Streptomyces koganeiensis ATCC 31394, including the N-terminal amino acid sequence AGENGATTTFDGPVA and having a molecular weight of 21.6 kDa, an isoelectric point (pI) in the range from 4.4 to 4.8 and enzymatic activity higher than 40000 IU/mg and lower than 50000 IU/mg. Described pharmaceutical or veterinary composition, containing the said hyaluronidase in a mixture with at least one suitable auxiliary substance and/or a carrier for treating diseases or states, for which decomposition of hyaluronic acid in tissues and organs is required or useful. The application of the said hyaluronidase as a reagent for the quantitative/qualitative determination of hyaluronic acid is claimed. The method of obtaining hyaluronic acid in accordance with the claimed invention includes the following stages: a) concentration by ultrafiltration through a filter with 10 kDA cut-off, dialysis of the supernatant, obtained after the fermentation of Streptomyces koganeiensis ATCC 31394, chromatography on a weak cation-exchanger by the elution of the column with a sodium-acetate buffer at pH 4.5 and separation of a protein fraction with hyaluronidase activity； b) diafiltration and chromatography of the protein fraction with hyaluronidase activity from stage a) on a strong anion-exchanger, separation of the protein fraction with hyaluronidase activity by the elution of the column with the buffer TRIS-HC1 and NaCl at pH 8 and separation of the protein fraction with hyaluronidase activity； c) chromatography of the protein fraction with hyaluronidase activity from stage b) on a strong cation-exchanger by the elution with a sodium phosphate buffer at pH 4.8 and separation of the protein fraction with hyaluronidase activity； d) chromatography of the protein fraction with hyaluronidase activity from stage C on a strong anion-exchanger after bringing pH to 5 and elut
